Skip to Content

XORTX Therapeutics Inc XRTXF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

XORTX Therapeutics Inc is focused on developing drug therapies for orphan disease like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes.

Contact
745 Thurlow Street, Suite 2400
Vancouver, BC, V6E 0C5, Canada
T +1 403 607-2621
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees